Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For more information, call 877-iCADnow, or visit "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995Ĭertain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.
Icad investor relations skin#
The Xoft System is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer.
![icad investor relations icad investor relations](https://pbs.twimg.com/media/FDxvVmwXIAg160w.jpg)
![icad investor relations icad investor relations](https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded/1295484/1295484-1545850298155-55aee5c6bd9a7.jpg)
iCAD's Xoft System, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. ICAD is an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. To schedule a meeting, contact Anne Marie Fields at or at 21 or contact your Needham & Company sales person. on January 17, 2013.Ĭompany management will be available for one-on-one meetings with investors participating in the Needham & Company Growth Conference. Ferry's presentation will take place at 3:30 p.m.
![icad investor relations icad investor relations](http://www.nmdc.com/public/uploadsData/textData/investors/CORPORATE_GOVERNANCE.jpg)
( NAS: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, announced today that Ken Ferry, iCAD's President and CEO, will provide a corporate overview and a discussion of the Company's growth strategy at the upcoming 15 th Annual Needham & Company Growth Conference taking place from January 15-17, 2013 at The Palace Hotel in New York City. NASHUA, N.H.-( BUSINESS WIRE)- iCAD, Inc. to Present at 15 th Annual Needham & Company Growth Conference